Power Law company profile

Revance Therapeutics

Biotech & Life Sciences · Nashville, United States · Founded 2002 · IPO 2014 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$643M

Market cap · 2026

Revenue

$234M

Latest reported FY

Investors

8 investors on Revance Therapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 8 investors entered at this stage

Bausch Health Companies

NovaQuest Capital Management

Essex Woodlands Health Ventures

EW Healthcare Partners

Global footprint

Where Revance Therapeutics has talent and traffic

AI talent share

0.7% of workforce is AI talent
(5 of 728 staff)

Core AI00%

Other AI50.69%

Non-AI workforce72399.31%

Web traffic by country

38K monthly visits
across markets

🇺🇸 United States77.4%

🇮🇳 India7.9%

🏳️ Korea4.5%

🏳️ Republic of3.2%

🇬🇧 United Kingdom2.6%

Top 5 markets shown

Patent intelligence

$41M patent portfolio · 28 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$41M

6.4% of market cap · 48.9× smaller than top peer Ablynx ($2B)

28 active patent families

Where Revance Therapeutics innovates Botulinum toxinPharmacologyToxinMedicineBotulinum toxin a

Below peer median on Legal, Strategic, Economic, Technology

Quality vs same-sector peers

Revance Therapeutics on the five Patsnap quality dimensions

Revance Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Revance Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Revance Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Revance Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo